Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study.

Transl Lung Cancer Res · 2024 · PMC11304151 · PMID 39118888

Europe PMC DOI

hedged sentences

0.4800

closest p · 9.6× alpha

0.4800

boldest claim

The sentences

an increasing trendP=0.48not close (p > 0.1)

Notably, the anlotinib group showed an increasing trend in ORR (20.0% vs. 7.7%, P=0.48) and a significant increase in DCR (70.0% vs. 23.1%, P=0.007).

also in 63,971 other papers

did not reach statistical significanceno p-value reported

Although the median OS in the anlotinib group (9.1 months) was longer than in the topotecan group (7.7 months), the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.